Arcutis Biotherapeutics, Inc.

Contributing Author

Recent Articles by Arcutis Biotherapeutics, Inc.

Oct-30	Mother-Daughter Duo, Tori Spelling and Stella McDermott, Partner With Arcutis Biotherapeutics in the Free to Be Me Campaign, Urging People With Inflammatory Skin Conditions to Speak With Their Healthcare Provider About Long-Term Treatments ARQT GlobeNewswire
Oct-30	Arcutis Launches ZORYVE (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Children Ages 2 to 5 ARQT GlobeNewswire
Oct-28	Arcutis Outlines Strategy for Driving Sustainable Growth and Announces Third Quarter 2025 Financial Results ARQT GlobeNewswire
Oct-27	Arcutis to Present at Upcoming Investor Conferences ARQT GlobeNewswire
Oct-24	Arcutis to Present New Quality of Life and Long-Term Data with ZORYVE (roflumilast) Cream 0.15% and 0.05% for the Treatment of Atopic Dermatitis at the Fall Clinical Dermatology Conference ARQT GlobeNewswire
Oct-06	FDA Approves Arcutis' ZORYVE (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5 ARQT GlobeNewswire
Oct-03	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ARQT GlobeNewswire
Sep-29	Arcutis Biotherapeutics to Host Virtual Investor Day and Report Third Quarter 2025 Financial Results on October 28, 2025 ARQT GlobeNewswire
Sep-17	Arcutis To Present Multiple New ZORYVE (roflumilast) Data Analyses at European Academy of Dermatology and Venereology Congress ARQT GlobeNewswire
Sep-16	Allure Magazine Honors Arcutis' ZORYVE (roflumilast) with Prestigious Best of Beauty Breakthrough Award ARQT GlobeNewswire
Sep-05	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ARQT GlobeNewswire
Sep-03	Arcutis Submits Supplemental New Drug Application for ZORYVE (roflumilast) Cream 0.3% to Expand Indication for Treatment of Plaque Psoriasis in Children Ages 2 to 5 ARQT GlobeNewswire
Aug-19	Arcutis to Present at Upcoming Investor Conferences ARQT GlobeNewswire
Aug-08	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ARQT GlobeNewswire
Aug-06	Arcutis Announces Second Quarter 2025 Financial Results and Provides Business Update ARQT GlobeNewswire
Jul-23	Arcutis to Report Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025 ARQT GlobeNewswire
Jul-03	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ARQT GlobeNewswire
Jun-26	Arcutis' ZORYVE (roflumilast) Cream 0.15% Receives Strong Recommendation in American Academy of Dermatology Updated Guidelines for Adult Atopic Dermatitis ARQT GlobeNewswire
Jun-10	Arcutis Enrolls First Child in INTEGUMENT-INFANT Evaluating ZORYVE (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis ARQT GlobeNewswire
Jun-06	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ARQT GlobeNewswire
Jun-06	Arcutis to Present New Long-Term Results of ZORYVE (roflumilast) Cream at the 2025 Revolutionizing Atopic Dermatitis Conference ARQT GlobeNewswire
May-29	Arcutis to Present at the Goldman Sachs 46th Annual Global Healthcare Conference ARQT GlobeNewswire
May-22	Arcutis' ZORYVE (roflumilast) Topical Foam 0.3% Approved by U.S. FDA for the Treatment of Plaque Psoriasis in Adults and Adolescents Ages 12 and Older ARQT GlobeNewswire
May-15	New Consensus Statements on Impact of Genital Psoriasis on Patients from Genital Psoriasis Wellness Consortium Published in Journal of the European Academy of Dermatology and Venereology Clinical Practice ARQT GlobeNewswire
May-07	Arcutis Announces Publication of Positive Data from ARRECTOR Trial Evaluating ZORYVE (roflumilast) Foam 0.3% in Individuals with Psoriasis in Journal of American Medical Association Dermatology ARQT GlobeNewswire
May-06	Arcutis Announces First Quarter 2025 Financial Results and Provides Business Update ARQT GlobeNewswire
May-02	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ARQT GlobeNewswire

Arcutis Biotherapeutics, Inc.

Recent Articles by Arcutis Biotherapeutics, Inc.

Upgrade your FINVIZ experience